Clinical trials for “lagundi” as a COVID-19 therapeutic or supplement have been approved by the Department of Science and Technology-Philippine Council for Health Research and Development .
DOST Secretary Fortunato de la Peña said that the University of the Philippines -Manila Research Ethics Board has also provided the ethics clearance. The DOST started in April studying the effectiveness of certain herbal medicines against COVID-19. Researchers repurposed existing medications or supplements with anti-viral properties such as lagundi and tawa-tawa.“Alam naman natin na yung lagundi ay tanggap na yan bilang gamot sa ubo, sa mga respiratory ailments at yan ang kauna-unahang halamang gamot na nacommercialize through a DOST research as early as the late 80s ,” the secretary said.
In an interview last month, Dela Pena said: “You can create new formulations with lagundi and tawa-tawa. Even tough it has evidence in treating other diseases, we will be making a different formulation.”Meanwhile, the application for clearance from the Food and Drug Administration for the conduct of the trials is still ongoing according to the agency.
Meanwhile, Secretary Dela Pena said that tawa-tawa, a supplement for dengue, has also been approved by the DOST-PCHRD but has no clearance yet from UP Manila.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: manilabulletin - 🏆 25. / 51 Read more »
Source: inquirerdotnet - 🏆 3. / 86 Read more »